PT-141
Bremelanotide, Vyleesi
PT-141 (bremelanotide) is a melanocortin receptor agonist researched for its effects on sexual function in both men and women. It acts centrally via the hypothalamus rather than through vascular mechanisms, distinguishing it from PDE5 inhibitors. It received FDA approval as Vyleesi for HSDD in premenopausal women and is also used off-label in compounded form. Common side effects include transient nausea and flushing.